GO:0042975 peroxisome proliferator activated receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042975 (peroxisome proliferator activated receptor binding) is a molecular function describing the binding of a protein or ligand to PPAR alpha, beta/delta, or gamma.
• PPARs are ligand-activated transcription factors that control lipid metabolism, inflammation, and cell differentiation, and their binding partners determine tissue-specific responses [1,5].
• Key PPAR-binding proteins include FABP4, FABP5, NCOA1, NCOA2, NCOR1, NCOR2, MED1, and RXRA, which modulate PPAR transcriptional activity [5,1].
• Dysregulated PPAR binding is implicated in cancer, metabolic disorders, addiction, and intestinal injury [2,3,4,6,7].
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect PPAR-binding interfaces and their downstream effects [1,8].
• EDITGENE provides custom cell models and CRISPR library screening to study PPAR-binding proteins in disease contexts.
Description
Peroxisome proliferator activated receptor (PPAR) binding (GO:0042975) is a molecular function defined as binding to a peroxisome proliferator activated receptor, alpha, beta or gamma. PPARs are nuclear hormone receptors that regulate gene expression in response to fatty acids and synthetic ligands, and their binding partners include coactivators, corepressors, and fatty acid transport proteins [1,5]. This function is central to understanding how PPAR signaling is modulated in health and disease. Researchers study PPAR binding to identify therapeutic targets for metabolic disorders, cancer, and inflammatory conditions [1,2,4]. The binding event often involves ligand-dependent conformational changes that recruit coactivator complexes, leading to transcriptional activation of PPAR target genes. Disruption of PPAR binding can alter lipid homeostasis, immune responses, and cell proliferation, making it a critical area of biomedical research [1,6,7].
peroxisome proliferator activated receptor binding At A Glance
| GO ID | GO:0042975 |
|---|---|
| GO term | peroxisome proliferator activated receptor binding |
| Ontology | molecular_function |
| Synonym | PPAR binding |
| Definition | Binding to a peroxisome proliferator activated receptor, alpha, beta or gamma. |
| Major function | Mediates protein-ligand and protein-protein interactions that regulate PPAR transcriptional activity. |
| Related receptors | PPARA, PPARD, PPARG |
| Common binding partners | FABP4, FABP5, NCOA1, NCOA2, NCOR1, NCOR2, MED1, RXRA |
| Disease relevance | Cancer, metabolic syndrome, addiction, intestinal inflammation |
What Is GO:0042975?
GO:0042975 describes the binding of a molecule (protein, peptide, or ligand) to any peroxisome proliferator activated receptor (PPAR alpha, beta/delta, or gamma). This binding event is a molecular function that typically initiates or modulates PPAR-mediated transcriptional regulation. It encompasses interactions with coactivators, corepressors, and fatty acid-binding proteins that directly contact PPARs [1,5].
Why Is peroxisome proliferator activated receptor binding Important in Cell Biology?
PPAR binding is a pivotal molecular function because it links lipid signaling to gene expression programs that control energy balance, inflammation, and cell fate. Dysregulation of PPAR-binding proteins contributes to cancer progression, metabolic diseases, and addiction, making this function a prime target for drug discovery [2,4,6,7]. Understanding the precise binding mechanisms can reveal new therapeutic strategies and biomarkers.
• PPAR binding regulates lipid and glucose homeostasis, influencing obesity and diabetes.
• It modulates inflammatory responses in diseases such as colitis and LPS-induced intestinal injury.
• PPAR gamma binding is implicated in malignant diseases, including various cancers.
• PPAR alpha signaling is linked to hepatocarcinogenesis.
• PPAR beta/delta binding affects trophoblast function and implantation.
• PPAR binding is a novel drug target in addiction.
• Phytocompounds targeting PPAR beta/delta and redox signaling show promise in cancer therapy.
• Fatty acid binding proteins sense fatty acids to activate PPARs, highlighting the role of binding in metabolic sensing.
• CRISPR-based models enable precise dissection of PPAR-binding interfaces.
• Understanding PPAR binding can guide personalized medicine approaches for metabolic and inflammatory diseases [1,2].
Molecular Mechanism of peroxisome proliferator activated receptor binding
Ligand-dependent activation and conformational change
In simple terms: When a fatty acid or drug binds to PPAR, the receptor changes shape to allow other proteins to attach.
PPARs are activated by endogenous fatty acids and synthetic ligands, which bind to the ligand-binding domain and induce a conformational change that creates a binding surface for coactivators [1,5]. This binding event is the first step in PPAR-mediated transcription. Fatty acid binding proteins such as FABP4 and FABP5 can deliver ligands to PPARs, facilitating this activation.
Coactivator recruitment
In simple terms: After activation, PPAR recruits helper proteins that turn on target genes.
Ligand-bound PPARs recruit coactivator complexes containing NCOA1 (SRC-1), NCOA2 (GRIP1), and MED1, which bridge PPARs to the basal transcriptional machinery. This recruitment is a direct consequence of PPAR binding and is essential for target gene activation. The binding affinity and specificity of coactivators influence the magnitude and duration of the transcriptional response.
Corepressor exchange
In simple terms: In the absence of ligand, PPARs bind repressor proteins that keep target genes off.
Unliganded PPARs interact with corepressors such as NCOR1 and NCOR2, which recruit histone deacetylases to repress transcription. Ligand binding triggers the exchange of corepressors for coactivators, a process that requires direct binding of these proteins to PPAR. This dynamic exchange is critical for switching PPAR target genes on or off.
Heterodimerization with RXRA
In simple terms: PPAR partners with another receptor, RXRA, to bind DNA and regulate genes.
PPARs form obligate heterodimers with retinoid X receptor alpha (RXRA), and this dimerization is necessary for DNA binding to peroxisome proliferator response elements (PPREs). The PPAR-RXRA heterodimer binds to PPREs in target gene promoters, and the binding of coactivators to this complex modulates transcriptional output. RXRA binding is a key component of the PPAR binding function.
Post-translational modifications and regulation
In simple terms: Chemical tags on PPARs can change how they bind to partners.
Phosphorylation, SUMOylation, and ubiquitination of PPARs can alter their binding to coactivators and corepressors, thereby modulating transcriptional activity. These modifications provide additional layers of regulation for PPAR binding. For example, phosphorylation of PPAR gamma by CDK5 has been shown to affect its binding properties and metabolic effects.
Key Genes Involved in GO:0042975 peroxisome proliferator activated receptor binding
The following genes encode proteins that directly bind to PPARs or are PPARs themselves, playing critical roles in PPAR signaling and disease.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PPARA | Nuclear receptor activated by fatty acids and fibrates | Regulates lipid metabolism; target in hepatocarcinogenesis |
| PPARD | Nuclear receptor involved in fatty acid oxidation | Modulates inflammation and cancer; target in trophoblast research |
| PPARG | Nuclear receptor controlling adipogenesis and insulin sensitivity | Central to diabetes and cancer research |
| FABP4 | Fatty acid binding protein that delivers ligands to PPARs | Links lipid sensing to PPAR activation |
| FABP5 | Fatty acid binding protein facilitating PPAR beta/delta activation | Involved in lipid signaling and cancer |
| NCOA1 | Transcriptional coactivator for PPARs | Enhances PPAR target gene expression |
| NCOA2 | Transcriptional coactivator for PPARs | Modulates PPAR-mediated transcription |
| NCOR1 | Corepressor that binds unliganded PPARs | Represses PPAR target genes |
| NCOR2 | Corepressor that binds unliganded PPARs | Represses PPAR target genes |
| MED1 | Mediator subunit that bridges PPARs to RNA polymerase II | Essential for PPAR-driven transcription |
| RXRA | Retinoid X receptor alpha, heterodimer partner of PPARs | Required for DNA binding and PPAR function |
| CDK5 | Kinase that phosphorylates PPAR gamma | Modulates PPAR binding and activity |
| EP300 | Histone acetyltransferase coactivator | Enhances PPAR transcriptional activity |
| CREBBP | Histone acetyltransferase coactivator | Interacts with PPARs to activate transcription |
| SRC | Proto-oncogene tyrosine kinase | May influence PPAR signaling indirectly |
| NRIP1 | Nuclear receptor interacting protein 1, corepressor | Modulates PPAR activity |
| PPARGC1A | Transcriptional coactivator PGC-1alpha | Regulates PPAR target genes in energy metabolism |
How Is peroxisome proliferator activated receptor binding Regulated?
PPAR binding is regulated by ligand availability, post-translational modifications, and the expression levels of coactivators and corepressors [1,5]. Fatty acid binding proteins such as FABP4 and FABP5 sense fatty acids and facilitate PPAR activation, thereby influencing binding events. Additionally, phosphorylation of PPARs by kinases like CDK5 can alter their binding affinity for coactivators, affecting downstream transcription. The balance between coactivator and corepressor binding is a key regulatory node in PPAR signaling.
peroxisome proliferator activated receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PPARG | Cancer, diabetes, inflammation | Knockout and point mutation cell lines |
| PPARA | Hepatocarcinogenesis | Liver-specific knockout models |
| PPARD | Cancer, trophoblast function | Overexpression and knock-in models |
| FABP4 | Metabolic disorders | CRISPR knockout in adipocytes |
| NCOA1 | Cancer, metabolic syndrome | Knock-in of binding-deficient mutants |
PPAR binding in cancer
PPAR binding proteins are implicated in multiple cancers. PPAR gamma binding is associated with malignant diseases, where it can either promote or suppress tumor growth depending on context. PPAR alpha signaling has been linked to hepatocarcinogenesis, with altered binding of coactivators contributing to liver cancer progression. Targeting PPAR beta/delta binding with phytocompounds has emerged as a strategy for cancer therapy, modulating reactive oxygen species and redox signaling.
PPAR binding in metabolic and inflammatory disorders
Dysregulated PPAR binding contributes to metabolic syndrome, diabetes, and inflammation. PPAR gamma binding is critical for insulin sensitivity and adipocyte differentiation. In intestinal inflammation, PPAR gamma activation via binding of protective compounds like berberine can attenuate LPS-induced injury. PPAR beta/delta and gamma agonists differentially affect prostaglandin E2 and cytokine synthesis in trophoblast cells, highlighting the role of binding in reproductive biology.
PPAR binding in addiction
PPARs have emerged as novel drug targets in addiction. PPAR binding modulates neuroinflammatory and reward pathways, and targeting PPARs may offer therapeutic benefits for substance use disorders.
From peroxisome proliferator activated receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PPARG knockout affect lipid metabolism? | CRISPR knockout in HepG2 or 3T3-L1 cells |
| How does a point mutation in PPARA alter ligand binding? | Point mutation knock-in in hepatocytes |
| Can overexpression of NCOA1 enhance PPAR target genes? | Overexpression cell lines |
| What is the interactome of PPAR gamma? | Tagged knock-in (e.g., GFP-PPARG) followed by proteomics |
| Does FABP4 mediate fatty acid delivery to PPARs? | FABP4 knockout and rescue experiments |
| How does PPAR beta/delta binding affect cytokine synthesis? | Knockout in trophoblast cells |
How to Study the peroxisome proliferator activated receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Luciferase reporter assay | PPAR transcriptional activity | Screening for PPAR ligands and coactivators |
| Co-immunoprecipitation | Protein-protein interactions | Validating PPAR-coactivator binding |
| CRISPR knockout screen | Gene essentiality for PPAR signaling | Identifying novel regulators of PPAR binding |
| RNA-seq | Transcriptional changes | Measuring PPAR target gene expression |
| Proteomics | Protein abundance and interactions | Mapping PPAR interactome |
| ChIP-seq | PPAR DNA binding sites | Identifying PPREs genome-wide |
| FRET/BRET | Real-time binding dynamics | Studying PPAR conformational changes |
Transcriptional reporter assays
PPAR binding can be assessed using luciferase reporters driven by PPREs. This method measures the functional consequence of PPAR binding and coactivator recruitment.
Co-immunoprecipitation and pull-down assays
These techniques detect direct physical interactions between PPARs and binding partners such as coactivators and corepressors. They are essential for validating binding events [1,5].
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate PPAR binding and signaling. These screens are powerful for discovering novel modulators.
Proteomics and interactomics
Mass spectrometry-based proteomics can map the PPAR interactome under different ligand conditions, revealing dynamic changes in binding partners.
How CRISPR Can Be Used to Study GO:0042975 peroxisome proliferator activated receptor binding
Knockout
CRISPR knockout of PPAR genes or their binding partners (e.g., NCOA1, FABP4) can abolish specific binding events, allowing researchers to study loss-of-function phenotypes in lipid metabolism and inflammation [1,5].
Point Mutation
Introducing point mutations in the ligand-binding domain of PPARs or in coactivator interaction surfaces can dissect the precise residues required for binding, providing mechanistic insights.
Knock-in
Knock-in of tagged PPARs (e.g., GFP or HA) enables affinity purification and imaging of PPAR binding complexes in live cells, facilitating interactome studies.
Overexpression
Overexpression of PPARs or their coactivators can amplify binding events and downstream transcriptional responses, useful for gain-of-function studies and drug screening.
How EDITGENE Supports peroxisome proliferator activated receptor binding Research
Researchers studying peroxisome proliferator activated receptor binding-related genes often need to determine whether a candidate gene is causally involved in PPAR signaling or disease. EDITGENE provides tailored CRISPR cell models and screening services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for peroxisome proliferator activated receptor binding research.
Frequently Asked Questions About peroxisome proliferator activated receptor binding
What is peroxisome proliferator activated receptor binding?
It is a molecular function (GO:0042975) defined as binding to a peroxisome proliferator activated receptor, alpha, beta or gamma.
What genes are involved in peroxisome proliferator activated receptor binding?
Key genes include PPARA, PPARD, PPARG, FABP4, FABP5, NCOA1, NCOA2, NCOR1, NCOR2, MED1, and RXRA [1,5].
How does PPAR binding regulate transcription?
Ligand binding to PPARs induces conformational changes that recruit coactivators and release corepressors, leading to target gene activation.
What diseases are associated with PPAR binding?
PPAR binding is implicated in cancer, metabolic disorders, addiction, and intestinal inflammation [2,3,4,6,7].
What is the role of FABP4 in PPAR binding?
FABP4 is a fatty acid binding protein that delivers ligands to PPARs, facilitating their activation.
How can I study PPAR binding using CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of PPAR binding interfaces and their effects.
What are the coactivators of PPARs?
NCOA1, NCOA2, and MED1 are key coactivators that bind to PPARs upon ligand activation.
What is the role of PPAR gamma in cancer?
PPAR gamma binding is associated with malignant diseases, where it can influence tumor growth and differentiation.
How is PPAR binding regulated?
PPAR binding is regulated by ligand availability, post-translational modifications, and the balance of coactivators and corepressors [1,5].
What model systems are used to study PPAR binding?
Common models include knockout and knock-in cell lines, reporter assays, and CRISPR screens [1,8].
Conclusion
GO:0042975 peroxisome proliferator activated receptor binding is a fundamental molecular function that governs PPAR-mediated transcriptional programs in metabolism, inflammation, and cancer. Understanding the precise binding events and their regulators offers opportunities for therapeutic intervention. EDITGENE's CRISPR services provide robust tools to investigate PPAR binding in disease-relevant models.
References
- 1. Wagner N et al.. 2020. The Role of PPARs in Disease.. Cells 9(11) PMID: 33126411
- 2. Quiroga C et al.. 2021. The Role of Peroxisome Proliferator-Activated Receptor in Addiction: A Novel Drug Target.. Curr Top Med Chem 21(11):964-975 PMID: 34061003
- 3. Izadparast F et al.. 2022. Protective effect of berberine against LPS-induced injury in the intestine: a review.. Cell Cycle 21(22):2365-2378 PMID: 35852392
- 4. Kaur C et al.. 2024. Targeting Peroxisome Proliferator-Activated Receptor-β/δ, Reactive Oxygen Species and Redox Signaling with Phytocompounds for Cancer Therapy.. Antioxid Redox Signal 41(4-6):342-395 PMID: 38299535
- 5. Wolfrum C. 2007. Cytoplasmic fatty acid binding protein sensing fatty acids for peroxisome proliferator activated receptor activation.. Cell Mol Life Sci 64(19-20):2465-76 PMID: 17876520
- 6. Misra P et al.. 2013. Peroxisome proliferator-activated receptor-α signaling in hepatocarcinogenesis.. Subcell Biochem 69:77-99 PMID: 23821144
- 7. Wang T et al.. 2006. Peroxisome proliferator-activated receptor gamma in malignant diseases.. Crit Rev Oncol Hematol 58(1):1-14 PMID: 16388966
- 8. Blitek A et al.. 2020. Peroxisome proliferator-activated receptor β/δ and γ agonists differentially affect prostaglandin E2 and cytokine synthesis and nutrient transporter expression in porcine trophoblast cells during implantation.. Theriogenology 152:36-46 PMID: 32361305
